SymBio Pharmaceuticals Ltd (4582)

Tokyo

Currency in JPY

156.0

-2.0(-1.27%)

Closed·08/08

Fair Value

Unlock Value

Day's Range

156.0

164.0

52 wk Range

126.0

329.0

4582 Financial Summary

A brief financial summary of SymBio Pharmaceuticals Ltd as well as the most significant critical numbers from each of its financial reports. In addition, some financial ratios derived from these reports are featured. Users can opt to see 4 periods of either annual or quarterly information.

Key Ratios

P/E Ratio-1.61

Price/Book3.3

Debt / Equity54.99%

Return on Equity-105.8%

Dividend Yield0.00%

EBITDA-3.78B

Fair ValueUnlock

Fair Value UpsideUnlock

Statements Highlights

Period Ending:

2015

31/12

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

2023

31/12

2024

31/12

Income Statement

Total Revenues

aa.aa

2,987.05

8,256.92

10,008

5,589

2,452

Gross Profit

aa.aa

866.85

5,804.45

7,600

4,410

1,873

Operating Income

aa.aa

-4,506.22

1,016

1,964

-812

-3,877

Net Income

aa.aa

-4,090.22

2,032.2

1,179

-1,962

-3,833

Balance Sheet

Total Assets

aa.aa

6,274.71

8,453

10,433

8,170

4,968

Total Current Liabilities

aa.aa

1,615.34

1,518.11

1,923

956

766

Total Equity

aa.aa

4,657.32

6,745.67

8,505

7,210

4,195

Cash Flow

Levered Free Cash Flow

aa.aa

-3,018.97

-226.95

1,542.12

-143.5

-2,055.13

Cash from Operations

aa.aa

-4,122.48

140.04

1,614

-194

-3,416

Cash from Investing

aa.aa

-160.31

-70.85

-47

-376

-3

Cash from Financing

aa.aa

4,222.09

-71.92

627

680

708

Net Change in Cash

aa.aa

-62.2

11.48

2,421

234

-2,553

* In Millions of JPY (except for per share items)

Earnings

Latest Release

Jul 31, 2025

EPS / Forecast

-21.49 / --

Revenue / Forecast

381.98M / --

EPS Revisions

Unlock

Last 90 days

FAQ

What were SymBio Pharmaceuticals's earnings for the latest quarter?

The SymBio Pharmaceuticals EPS (TTM) is -99.35. SymBio Pharmaceuticals reported sales of 382.62, net income of -1,047.71, and EPS of -21.49 for the latest quarter.

What was SymBio Pharmaceuticals's net income for the latest quarter?

SymBio Pharmaceuticals's net income for the latest quarter was -1,047.71.

How did SymBio Pharmaceuticals's performance compare year-over-year in the latest quarter?

The company's revenue moved from 264.02 in the previous quarter to 382.62 in the latest quarter, and net income moved from -1,321.48 to -1,047.71 compared to the previous quarter.

What is SymBio Pharmaceuticals's net profit margin on a TTM basis?

SymBio Pharmaceuticals's trailing twelve months (TTM) net profit margin is -156.32%.

How does SymBio Pharmaceuticals's debt to equity ratio compare to industry standards?

SymBio Pharmaceuticals's total debt-to-equity ratio is 54.99%.

What is SymBio Pharmaceuticals's return on investment on a TTM basis?

SymBio Pharmaceuticals's trailing twelve months (TTM) return on investment (ROI) is -105.80%.

What were SymBio Pharmaceuticals's total assets and liabilities in the latest quarter?

As of the latest quarter, SymBio Pharmaceuticals reported total assets of 4,139.08 million and total liabilities of 470.23 million.

How has SymBio Pharmaceuticals's total revenue grown this year?

SymBio Pharmaceuticals's total revenue was 264.02 in the previous quarter and 382.62 in the latest quarter.

What is SymBio Pharmaceuticals's gross margin on a TTM basis?

SymBio Pharmaceuticals's trailing twelve months (TTM) gross margin is 75.50%.

What was SymBio Pharmaceuticals's revenue per share for the latest quarter?

SymBio Pharmaceuticals's revenue per share for the latest quarter was 1,937.45.

NSE 30

5,327.45

-37.59

-0.70%

NSE All Share

145,756.52

-814.18

-0.56%

US 30

44,245.50

+276.8

+0.63%

US 500

6,401.30

+61.3

+0.97%

FTSE 100

9,095.73

-5.04

-0.06%

DAX

24,162.86

-29.64

-0.12%

South Africa Top 40

93,492.91

+187.14

+0.20%

Market Movers

Name	Last	Chg. %	Vol.
Access Holdings	27.60	+0.73%	55.01M
UBA	48.60	+0.31%	36.07M
Zenith Bank	74.65	-0.07%	28.81M
Dangote Cement	577.00	0.00%	13.64M
Guaranty Trust Holding	100.00	+0.05%	13.62M
MTN Nigeria	460.00	-4.17%	4.24M
Seplat Petroleum	5,450.00	0.00%	257.89K

Name	Last	Chg. %	Vol.
Champion Brew	14.41	+10.00%	2.47M
Universal Insurance PLC	1.10	+10.00%	213.19M
Union Dicon Salt	9.90	+10.00%	294.72K
Guinness Nigeria	155.75	+9.99%	1.48M
Mansard Ins	14.640	+9.99%	6.40M
Cornerst	6.41	+9.95%	14.20M
Ellah Lakes	13.28	+9.93%	30.28M

Name	Last	Chg. %	Vol.
Abbey Mortgage Bank	6.30	-9.87%	2.47M
Custodian Allied	40.45	-8.48%	3.64M
Deap Capital Management Trust	1.35	-7.53%	1.73M
Initiates	12.00	-7.34%	5.85M
Npfmcrfbk	3.200	-7.25%	3.03M
Omatek Ventures	1.35	-6.90%	10.53M
Honeywell Flour Mills Plc	24.800	-6.42%	3.39M

Trending Stocks

Name	Last	Chg. %	Vol.
VFD PLC	13.40	+0.75%	9.75M
Initiates	12.00	-7.34%	5.85M
Aiico	3.50	+9.72%	178.52M
UBA	48.60	+0.31%	36.07M
Ellah Lakes	13.28	+9.93%	30.28M

Most Undervalued Stocks

Name	Last	Upside	Fair Value
A Aaaaaaaaaaaaaaaa	5,450.00	+49.03%	8,122.13
Aaaaaa A A Aaaaaaaa	1,890.00	+34.28%	2,537.89
Aaa Aa Aaaa	577.00	+28.58%	741.91
Aaaa A	640.00	+16.45%	745.28
Aaaaaa Aa A Aa	74.00	+15.80%	85.69

See full list

Install Our AppScan QR code to install app

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers

Popular Searches

Please try another search

SymBio Pharmaceuticals Ltd (4582)

4582 Financial Summary

Key Ratios

Statements Highlights

Earnings

FAQ

What were SymBio Pharmaceuticals's earnings for the latest quarter?

What was SymBio Pharmaceuticals's net income for the latest quarter?

How did SymBio Pharmaceuticals's performance compare year-over-year in the latest quarter?

What is SymBio Pharmaceuticals's net profit margin on a TTM basis?

How does SymBio Pharmaceuticals's debt to equity ratio compare to industry standards?

What is SymBio Pharmaceuticals's return on investment on a TTM basis?

What were SymBio Pharmaceuticals's total assets and liabilities in the latest quarter?

How has SymBio Pharmaceuticals's total revenue grown this year?

What is SymBio Pharmaceuticals's gross margin on a TTM basis?

What was SymBio Pharmaceuticals's revenue per share for the latest quarter?

Trending Stocks